Coherus Oncology, Inc. (CHRS)
1.37
+0.02
(+1.48%)
USD |
NASDAQ |
Sep 21, 16:00
1.39
+0.02
(+1.46%)
After-Hours: 20:00
Coherus Oncology Price to Book Value : 3.478 for Sept. 21, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 21, 2026 | 3.478 |
| September 18, 2026 | 3.428 |
| September 17, 2026 | 3.123 |
| September 16, 2026 | 3.098 |
| September 15, 2026 | 3.377 |
| September 14, 2026 | 3.631 |
| September 11, 2026 | 3.377 |
| September 10, 2026 | 3.402 |
| September 09, 2026 | 3.352 |
| September 08, 2026 | 3.478 |
| September 04, 2026 | 3.605 |
| September 03, 2026 | 3.478 |
| September 02, 2026 | 3.605 |
| September 01, 2026 | 3.478 |
| August 31, 2026 | 3.428 |
| August 28, 2026 | 3.58 |
| August 27, 2026 | 3.707 |
| August 26, 2026 | 3.682 |
| August 25, 2026 | 3.478 |
| August 24, 2026 | 3.453 |
| August 21, 2026 | 3.605 |
| August 20, 2026 | 3.352 |
| August 19, 2026 | 3.377 |
| August 18, 2026 | 3.402 |
| August 17, 2026 | 2.920 |
| Date | Value |
|---|---|
| August 14, 2026 | 3.047 |
| August 13, 2026 | 2.894 |
| August 12, 2026 | 2.971 |
| August 11, 2026 | 3.072 |
| August 10, 2026 | 3.148 |
| August 07, 2026 | 3.225 |
| August 06, 2026 | 3.212 |
| August 05, 2026 | 3.682 |
| August 04, 2026 | 3.758 |
| August 03, 2026 | 3.656 |
| July 31, 2026 | 3.58 |
| July 30, 2026 | 3.732 |
| July 29, 2026 | 3.58 |
| July 28, 2026 | 3.656 |
| July 27, 2026 | 3.707 |
| July 24, 2026 | 3.58 |
| July 23, 2026 | 3.631 |
| July 22, 2026 | 3.631 |
| July 21, 2026 | 3.732 |
| July 20, 2026 | 3.605 |
| July 17, 2026 | 3.555 |
| July 16, 2026 | 3.529 |
| July 15, 2026 | 3.656 |
| July 14, 2026 | 3.682 |
| July 13, 2026 | 3.732 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Enanta Pharmaceuticals, Inc. | 3.489 |
| ACADIA Pharmaceuticals, Inc. | 3.477 |
| Alnylam Pharmaceuticals, Inc. | 24.13 |
| Anika Therapeutics, Inc. | 2.018 |
| Savara, Inc. | 7.792 |
Price to Book Value Related Metrics
| PS Ratio | 3.549 |
| Price | 1.37 |
| Earnings Yield | -74.54% |
| Market Cap | 211.62M |